The story
Japan has given GSK's velzatinib orphan drug status for gastrointestinal stromal tumours, and pivotal data are expected in 2027.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.